Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment

Thomas Marbury, Eric Lawitz, Robert Stonerock, Martha Gonzalez, James Jiao, Jim Breeding, Christopher Haqq, Peter Verboven, Hans Stieltjes, Margaret Yu, Arturo Molina, Milin Acharya, Caly Chien, Namphuong Tran

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Three open-label, single-dose studies investigated the impact of hepatic or renal impairment on abiraterone acetate pharmacokinetics and safety/tolerability in non-cancer patients. Patients (n=8 each group) with mild/moderate hepatic impairment or end-stage renal disease (ESRD), and age-, BMI-matched healthy controls received a single oral 1,000mg abiraterone acetate (tablet dose); while patients (n=8 each) with severe hepatic impairment and matched healthy controls received 125- and 2,000-mg abiraterone acetate (suspension doses), respectively (systemic exposure of abiraterone acetate suspension is approximately half to that of tablet formulation). Blood was sampled at specified timepoints up to 72 or 96hours postdose to measure plasma abiraterone concentrations. Abiraterone exposure was comparable between healthy controls and patients with mild hepatic impairment or ESRD, but increased by 4-fold in patients with moderate hepatic impairment. Despite a 16-fold reduction in dose, abiraterone exposure in patients with severe hepatic impairment was about 22% and 44% of the Cmax and AUC of healthy controls, respectively. These results suggest that abiraterone pharmacokinetics were not changed markedly in patients with ESRD or mild hepatic impairment. However, the capacity to eliminate abiraterone was substantially compromised in patients with moderate or severe hepatic impairment. A single-dose administration of abiraterone acetate was well-tolerated.

Original languageEnglish (US)
Pages (from-to)732-741
Number of pages10
JournalJournal of Clinical Pharmacology
Volume54
Issue number7
DOIs
StatePublished - Jul 2014

Keywords

  • abiraterone acetate
  • hepatic impairment
  • pharmacokinetics
  • phase-I
  • renal impairment

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Single-dose pharmacokinetic studies of abiraterone acetate in men with hepatic or renal impairment'. Together they form a unique fingerprint.

Cite this